- The stock price of Abiomed (NASDAQ: ABMD) fell by over 5% during intraday trading today. This is why it happened.
The stock price of Abiomed (NASDAQ: ABMD) fell by over 5% during intraday trading today. Investors are responding negatively to the company’s third-quarter results.
Abiomed reported third-quarter EPS of $1.13, which was $0.16 better than analyst estimates of $0.97. And the revenue for the quarter was $261 million compared to a consensus estimate of $253.8 million.
In terms of guidance, Abiomed sees FY2022 revenue of $1.025-1.03 billion compared to a consensus of $1.02 billion. Despite what appears to be a favorable quarter, Abiomed was unable to fend off the broader market selloff today.
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.